In relation to MM, G protein coupled receptor, family C, group 5, member D (GPRC5D) emerged more recently as another compelling target, whose expression on MM cells is independent of BCMA.39,40 Engineering bispecific CAR T cells with a tandem of nanobodies against BCMA and GPRC5D respectively could possibly target a more complete spectrum of MM cells, circumvent single antigen escape, and ultimately elicit deeper and more durable clinical response. This evidence concerns the gene GPRC5D and Miyoshi myopathy.